COVID Disease 7 months after first booster; This spontaneous case was reported by a pharmacist and describes the occurrence of COVID-19 (COVID Disease 7 months after first booster) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039D21A, 079L20A and 079L20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Jun-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (COVID Disease 7 months after first booster). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID Disease 7 months after first booster) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. The pharmacist asked that, if the patient could receive the 2nd booster of Moderna COVID-19 vaccine that day or not as the patient received the 3 doses of Moderna vaccine and had COVID disease on 02 JUN 2022.  Company comment: This is a spontaneous case reported by pharmacist, concerning a 52-year-old, female patient with no reported medical history. Patient experienced the unexpected non-serious AESI event of Covid-19. It was reported that the patient received first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 29 days with the same lot/batch number of 079L20A. The patient received third dose (first booster dose) of mRNA-1273 vaccine approximately 242 days after the second dose of mRNA-1273 vaccine. The event Covid-19 occurred 220 days after the third dose (first booster dose) of mRNA-1273. It was reported that the patient was treated with Nirmatrelvir + Ritonavir (Paxlovid). No further clinical information was available for medical review. The current Covid-19 pandemic remain confounder for the event Covid-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case reported by pharmacist, concerning a 52-year-old, female patient with no reported medical history. Patient experienced the unexpected non-serious AESI event of Covid-19. It was reported that the patient received first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 29 days with the same lot/batch number of 079L20A. The patient received third dose (first booster dose) of mRNA-1273 vaccine approximately 242 days after the second dose of mRNA-1273 vaccine. The event Covid-19 occurred 220 days after the third dose (first booster dose) of mRNA-1273. It was reported that the patient was treated with Nirmatrelvir + Ritonavir (Paxlovid). No further clinical information was available for medical review. The current Covid-19 pandemic remain confounder for the event Covid-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.